tradingkey.logo

Tempus AI Inc

TEM
View Detailed Chart

86.380USD

-2.400-2.70%
Close 09/12, 16:00ETQuotes delayed by 15 min
15.00BMarket Cap
LossP/E TTM

Tempus AI Inc

86.380

-2.400-2.70%
Intraday
1m
30m
1h
D
W
M
D

Today

-2.70%

5 Days

+8.49%

1 Month

+24.06%

6 Months

+104.86%

Year to Date

+155.86%

1 Year

+74.93%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated2025-09-12

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
6 / 507
Overall Ranking
107 / 4724
Industry
Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 15 analysts
Buy
Current Rating
73.409
Target Price
-7.80%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Tempus AI, Inc. is a technology company. The Company provides next generation diagnostics across multiple disease areas, with technology capabilities, harnessing the data and analytics to help personalize medicine. The Company’s product lines include genomics, data, and artificial intelligence applications (AI). Its genomics product line leverages its laboratories to provide next generation sequencing, diagnostics, polymerase chain reaction (PCR), profiling, molecular genotyping, and other anatomic and molecular pathology testing. The Company's AI applications are focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools. Its primary product of AI applications is Next, an AI platform that leverages machine learning to apply an intelligent layer onto routinely generated data to proactively identify and minimize care gaps for oncology and cardiology patients.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 116.24% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 123.50.
Overvalued
The company’s latest PE is 40.31, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 136.83M shares, decreasing 2.27% quarter-over-quarter.
Held by Baillie Gifford
Star Investor Baillie Gifford holds 12.09M shares of this stock.

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Tempus AI, Inc. is a technology company. The Company provides next generation diagnostics across multiple disease areas, with technology capabilities, harnessing the data and analytics to help personalize medicine. The Company’s product lines include genomics, data, and artificial intelligence applications (AI). Its genomics product line leverages its laboratories to provide next generation sequencing, diagnostics, polymerase chain reaction (PCR), profiling, molecular genotyping, and other anatomic and molecular pathology testing. The Company's AI applications are focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools. Its primary product of AI applications is Next, an AI platform that leverages machine learning to apply an intelligent layer onto routinely generated data to proactively identify and minimize care gaps for oncology and cardiology patients.
Ticker SymbolTEM
CompanyTempus AI Inc
CEOMr. Eric P. Lefkofsky, J.D.
Websitehttps://www.tempus.com/
KeyAI